Losartan Potassium Tablets Recalled Due to NMBA Impurity Detection
Golden State Medical Supply Inc. is recalling Losartan Potassium 100 mg tablets because an impurity called NMBA was detected in the active ingredient.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe rating under the rubric, particularly given the detection of a nitrosamine impurity (NMBA) in the active pharmaceutical ingredient.
Plain-English summary
Golden State Medical Supply Inc. is recalling Losartan Potassium, 100 mg tablets, 90 count bottles (NDC 60429-318-90). The recall involves 32,835 bottles, totaling 2,955,150 tablets. The affected lots are GS017042, GS017043, GS017044, and GS017541, all with an expiration date of 01/2020.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, an impurity known as N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) was detected in the active pharmaceutical ingredient (API) used to manufacture the finished products.
The affected product was distributed to one U.S. government account nationwide. No foreign accounts were involved. Consumers and healthcare providers should check their inventory for the specific NDC and lot numbers listed above and stop using the product if it matches the recall details.
The recalled product
- Product
- Losartan Potassium, 100 mg tablets, 90 count bottle, NDC 60429-318-90
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: GS017042
- Expiration 01/2020
- GS017043
- GS017044
- GS017541
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- SevereGolden State Medical Supply Recalls Prasugrel Tablets for Failed Dissolution
FDA (Drugs) · 2026-09-09
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- SevereLosartan Potassium Tablets Recalled Due to Impurity Presence
FDA (Drugs) · 2019-05-29
- SevereLosartan Potassium Tablets Recalled Due to NBMA Impurity Detection
FDA (Drugs) · 2020-04-22
- SevereMacleods Pharma Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-07-17
- SevereTeva Recalls Losartan Potassium Tablets Due to Impurity Detection
FDA (Drugs) · 2019-07-17
- SevereAvKARE Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-03-27
- SevereTeva Recalls Losartan Potassium Tablets Due to NMBA Impurity
FDA (Drugs) · 2020-04-15